Steve Poretz, RN, MSHA
Executive Director

The Clinical Alliance for Research and Education (CARE-ID) Records Its First Enrollees and Infusions for the Blaze-1 COVID-19 Clinical Trial

BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful laboratory studies

Annandale, VA; August 5, 2020 – CARE-ID announced today it has enrolled and infused the first participants (20% of its total trial goal) in a clinical research study to evaluate the safety and effectiveness of LY-CoV555 in patients with early mild to moderate COVID-19. Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is looking for adults ages 18 or older who have recently tested positive for COVID-19 and are not hospitalized.

LY-CoV555 is an antibody therapy engineered from one of the first individuals to recover from COVID-19, which may help newly diagnosed patients clear the SARS-CoV-2 virus faster. Laboratory studies have shown that LY-CoV555 binds with high affinity to the SARS-CoV-2 virus and neutralizes its ability to infect cells and replicate.

"We are very pleased to be off to a good start in our recruiting efforts and to have completed our first few treatment infusions. Clinical trials like BLAZE-1 are vital in testing potential treatments for COVID-19 which, if successful, represent medicines which can be used to protect those most at risk of severe illness, such as the elderly and immunocompromised," said David A. Wheeler, MD, FACP, FIDSA, CARE-ID principle investigator and president and managing partner of Infectious Diseases Physicians, Inc. (IDP), a private clinical practice focusing on the care of people with a range of infectious diseases. "CARE-ID is very pleased to join the front lines along with Lilly in the fight against COVID-19 to potentially bring an effective treatment to the public faster."

To be eligible for the BLAZE-1 Study, participants must have tested positive for SARS-CoV-2 infection within three days prior to the study drug infusion, and have one or more mild or moderate COVID-19 symptoms, including, fever, cough, sore throat, headache, muscle pain, nausea, abdominal pain, diarrhea, or shortness of breath when active.

If a person is eligible and decides to participate, the research staff at CARE-ID will perform specific tests and procedures to monitor the patient's health and how their body reacts to the LY-CoV555 antibody treatment. These tests and procedures include physical exams, vital sign measurements, blood samples, and nasopharyngeal swabs to measure levels of virus.

The study drug is being compared to a placebo, and both the study drug and the placebo will be administered as a single-dose intravenous (IV) infusion. Participants will be randomly selected to receive the placebo or the study drug.

"Kicking off the BLAZE-1 Study with research sites around the country, including CARE-ID, is a huge milestone for the global fight against COVID-19, and we're excited to bring the industry one step closer to a potential treatment," said Dr. Daniel Skovronsky, chief scientific officer, Eli Lilly and Company. "We look forward to working with eligible patients who are not only interested in receiving investigational treatments for COVID-19, but who also understand how their participation can impact the health and well-being of millions of people around the world."

CARE-ID is located and can be contacted at:

3289 Woodburn Rd. Suite 250
Annandale, Virginia 22003
info@careidresearch.com
703-560-4821 (phone)
703-641-8654 (fax)
http://www.careidresearch.com/

If someone has tested positive and exhibited symptoms for COVID-19, and are interested in participating in clinical research in their area, call 833.277.0197 or visit JoinCOVIDStudy.com to learn more.

About CARE-ID

CARE-ID conducts clinical research trials in the field of infectious diseases with particular focus on the safety and confidentiality of our participants, quality of our data, and integrity of our results. We partner with pharmaceutical and biotechnology companies to develop experimental therapies for both the prevention and treatment of infectious diseases.